Cytoplasmic signaling pathways that regulate cardiac hypertrophy

Annual Review of Physiology

Volumn 63, Issue , 2001, Pages 391-426

  Molkentin, J D ^a   Dorn II, G W ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cardiomyocytes; Heart failure; Kinase; Phosphatase; Signaling

Indexed keywords

CALCINEURIN; FIBROBLAST GROWTH FACTOR RECEPTOR; GLYCOPROTEIN GP 130; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROHORMONE; PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN KINASE C; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE WALL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; CYTOPLASM; HUMANS; MYOCARDIUM; SIGNAL TRANSDUCTION;

EID: 0035051054     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.63.1.391     Document Type: Review

References (213)

1. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study
2. The epidemiology of heart failure: The Framingham study
3. Trends of congestive heart failure epidemiology: Contrast with clinical trial results
4. Functional consequences of altering myocardial adrenergic receptor signaling
5. Catecholamines, cardiac beta-adrenergic receptors, and heart failure
6. Diversity of G proteins in signal transduction
7. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits
8. A direct interaction between G-protein beta gamma subunits and the Raf-1 protein kinase
9. G-beta gamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy
10. Genetically engineered mice: Model systems for left ventricular failure
11. Increase in myocardial Gi-proteins in heart failure
12. Al-adenosine receptor inhibition of adenylate cyclase in failing and nonfailing human ventricular myocardium
13. Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing
14. Desensitization of adenylate cyclase and increase of Gi alpha in cardiac hypertrophy due to acquired hypertension
15. Role of altered G-protein expression in the regulation of myocardial adenylate cyclase activity and force of contraction in spontaneous hypertensive cardiomyopathy in rats
16. Increased levels of inhibitory G protein in myocardium with heart failure
17. Myocardial Gi alpha-protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease and cardiogenic shock
18. Physiological and biochemical evidence for coordinate increases in muscarinic receptors and Gi during pacing-induced heart failure
19. Altered expression of alpha-subunits of G proteins in failing human hearts
20. Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure
21. Regulation of the human Gi alpha-2 gene promoter activity in embryonic chicken cardiomyocytes
22. Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice
23. Decreased Gs alpha mRNA levels accompany the fall in Gs and adenylyl cyclase activities in compensated left ventriculax hypertrophy. In heart failure, only the impairment in adenylyl cyclase activation progresses
24. Decreased stimulatory guanosine triphosphate binding protein in dogs with pressure-overload left ventricular failure
25. Differential alterations in left and fight ventriculax Gproteins in congestive heart failure due to myocardial infarction
26. Downregulation of cardiac guanosine 5′-triphosphate-binding proteins in right atrium and left ventricle in pacing-induced congestive heart failure
27. Cardiac adenylyl cyclase, beta-adrenergic receptors, and G proteins in salt-sensitive hypertension
28. Diminished responsiveness of Gs-coupled receptors in severely failing human hearts: No difference in dilated versus ischemic cardiomyopathy
29. Alterations in G-proteins in congestive heart failure in cardiomyopathic (UM-X7.1) hamsters
30. Overexpression of Gs alpha protein in the hearts of transgenic mice
31. sα overexpression
32. sα transgenic mice
33. Multiple extra-adrenal paragangliomas associated with catecholamine cardiomyopathy
34. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma
35. Focal myocarditis associated with pheochromocytoma
36. Phaeochromocytoma and catecholamine induced cardiomyopathy presenting as heart failure
37. 2 adrenergic receptor overexpression in mouse hearts: Critical role for expression level
38. 2-adrenergic receptors differentially affects cardiac hypertrophy and function in Gαq overexpressing mice
39. Progressive hypertrophy and heart failure in betal-adrenergic receptor transgenic mice
40. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response
41. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines
42. 2α stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes
43. 1-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy
44. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro
45. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly and cardiac gene expression in ventricular myocytes: A paracrine mechanism for myocardial cell hypertrophy
46. 2α-stimulated hypertrophic growth in neonatal rat cardiac myocytes is mediated by action of tyrosine kinases and Jun N-terminal kinase
47. Phosphoinositide-generated second messengers in cardiac signal transduction
48. Regulation of phospholipases C and D in rat ventricular myocytes: Stimulation by endothelin-1, bradykinin and phenylephrine
49. Phenylephrine and endothelin differentially stimulate cardiac PI hydrolysis and ANF expression
50. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro: Roles of phospholipid-derived second messengers
51. 1 muscarinic receptors heterologously expressed in cardiac myocytes mediates Ras-dependent changes in gene expression
52. Enhanced Gαq signaling: A common pathway mediates cardiac hypertrophy and heart failure
53. 1-adrenergic stimulation
54. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
55. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension
56. Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (Lisinopril) in essential hypertension
57. Regression of left ventricular hypertrophy from systemic hypertension by enalapril
58. Expression of Gqα and PLC-β in scar and border tissue in heart failure due to myocardial infarction
59. Transgenic Gαq overexpression induces cardiac contractile function in mice
60. Decompensation of pressure overload hypertrophy in Gαq overexpressing mice
61. Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways
62. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy
63. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload
64. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy
65. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice
66. Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene ex pression and increase cell size in neonatal rat ventricular myocytes
67. A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: Implications for cardiac hypertrophy
68. Effect of a dominant negative ras on myocardial hypertrophy by using adenoviral-mediated gene transfer
69. Increasing complexity of the Ras signaling pathway
70. The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy
71. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure
72. MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells
73. Angiotensin II activates RhoA in cardiac myocytes: A critical role of RhoA in angiotensin II-induced premyofibril formation
74. A requirement for the racl GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy
75. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1
76. Organization and regulation of mitogen-activated protein kinase signaling pathways
77. Mechanical loading activates mitogen-activated protein kinase and S6 peptide kinase in cultured rat cardiac myocytes
78. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes: The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy
79. Differential activation of protein kinase C isoforms by endothelin-1 and phenylephrine and subsequent stimulation of p42 and p44 mitogen-activated protein kinases in ventricular myocytes cultured from neonatal rat hearts
80. Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes
81. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes
82. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart, p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion
83. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G proteincoupled receptor agonists, endothelin-1 and phenylephrine: A role in cardiac myocyte hypertrophy?
84. The mitogen-activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophic phenotype in rat ventricular cardiomyocytes
85. Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes
86. Mitogen-activated protein kinases mediate changes in gene expression, but not cytoskeletal organization associated with cardiac muscle cell hypertrophy
87. Raf-1 kinase activity is necessary and sufficient for gene expression changes but not sufficient for cellular morphology changes associated with cardiac myocyte hypertrophy
88. Inhibition of a signaling pathway in cardiac muscle cells by active mitogen-activated protein kinase kinase
89. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression
90. Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy
91. Extracellular signal-regulated protein kinase activation is required for the antihypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes
92. Stress-activated protein kinases: Activation, regulation and function
93. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium
94. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta
95. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family
96. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease
97. Oppos ing effects of Jun kinase and p38 mitogen activated protein kinases on cardiomyocyte hypertrophy
98. Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism
99. Endothelin-dependent and -independent components of strain-activated brain natriuretic peptide gene transcription require extracellular signal regulated kinase and p38 mitogen-activated protein kinase
100. Cell density and contraction regulate p38 MAP kinase-dependent responses in neonatal rat cardiac myocytes
101. JSAF1, a novel jun N-terminal protein kinase (INK)-binding protein that functions as a Scaffold factor in the JNK signaling pathway
102. Mechanical stretch activates the stress-activated protein kinases in cardiac myocytes
103. Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension
104. Activation of JNK in the remote myocardium after large myocardial infarction in rats
105. 2-terminal kinases
106. Studies and perspectives of protein kinase C
107. Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat
108. Angiotensin II-induced growth responses in isolated adult rat hearts: Evidence for load-independent induction of cardiac protein synthesis by angiotensin II
109. A selective ε-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death
110. Stimulus-dependent subcellular localization of activated protein kinase C; a study with acidic fibroblast growth factor and transforming growth factor-beta 1 in cardiac myocytes
111. Localization of protein kinase C isozymes in cardiac myocytes
112. Protein kinase C isoenzymes: Divergence in signal transduction?
113. Protein kinase C isoform diversity in the heart
114. Localization of protein kinases by anchoring proteins: A theme in signal transduction
115. A protein kinase C translocation inhibitor as an isozyme selective antagonist of cardiac function
116. An autoregulatory region in protein kinase C: The pseudoanchoring site
117. 2+ channels
118. Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation
119. Left ventricular stretch stimulates angiotensin II mediated phosphatidylinositol hydrolysis and protein kinase Cε isoform translocation in adult guinea pig hearts
120. 2-terminal kinase activation in the heart: Evidence of crosstalk between cardiac hypertrophic signaling pathways
121. Activation of epsilon protein kinase C correlates with a cardioprotective effect of regular ethanol consumption
122. Mechanisms of impaired beta-adrenergic receptor signaling in G(alphaq)-mediated cardiac hypertrophy and ventricular dysfunction
123. Protein kinase C isoform expression and regulation in the developing rat heart
124. Use of PCR-based method to characterize protein kinase C isoform expression in cardiac cells
125. Targeted overexpression of protein kinase Cβ2 isoform in myocardium causes cardiomyopathy
126. In vivo phosphorylation of cardiac troponin I by protein kinase C beta 2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts
127. Expression of protein kinase Cβ in the heart causes hypertrophy in adult mice and sudden death in neonates
128. Cardiotrophic effects of εprotein kinase C: Analysis by in vivo modulation of εPKC translocation
129. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin
130. Generic signals and specific outcomes: Signaling through calcium, calcineurin, and NF-AT
131. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy
132. Alterations in calcium handling in cardiac hypertrophy and heart failure
133. Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition
134. Prevention of cardiac hypertrophy in mice by calcineurin inhibition
135. Calcineurin and cardiac hypertrophy
136. Calcineurin inhibition and cardiac hypertrophy
137. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats
138. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin
139. Cyclosporine attenuates pressure overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure
140. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy
141. Calcineurin expression, activation, and function in cardiac pressure overload hypertrophy
142. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload, Hill LV function following calcineurin inhibition
143. Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes
144. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy
145. Development of an assay method for activities of serine/threonine protein phosphatase type 2B (calcineurin) in crude extracts
146. Superoxide dismutase protects calcineurin from inactivation
147. Calcineurin and human heart failure
148. Reply to revisiting calcineurin and human heart failure
149. Revisiting calcineurin and human heart failure
150. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine
151. Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins
152. Calcineurin-dependent nuclear translo cation of a murine transcription factor NFATx: Molecular cloning and functional characterization
153. NFATx, a novel member of the nuclear factor of activated T cells family that is expressed predominantly in the thymus
154. Cardiotrophin-1 and the role of gp130-dependent signaling pathways in cardiac growth and development
155. Cardiotrophin- 1 activates a distinct form of cardiac muscle cell hypertrophy: Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways
156. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130
157. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130
158. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components
159. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6
160. Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active Ras GTP complex in rat pheochromocytoma PC12 cells
161. Involvement of Janus kinases, p52shc, Raf-1, and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth-responsive B cell line
162. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes
163. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes
164. 2+]i transient in cardiomyocytes
165. Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart
166. gp130 is involved in stretch-induced MAP kinase activation in cardiac myocytes
167. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy
168. Leukemia inhibitory factor, a potent cardiac hypertrophic cy tokine, activates the JAK/STAT pathway in rat cardiomyocytes
169. Continuous activation of gp 130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice
170. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders
171. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress
172. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes
173. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy
174. Insulin-like growth factor I as a cardiac hormone: Physiological and pathophysiological implications in heart disease
175. PI 3-kinase: Structural and functional analysis of intersubunit inter-actions
176. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice
177. Effects of constitutive overexpression of insulin-like growth factor-1 on the mechanical characteristics and molecular properties of ventricular myocytes
178. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice
179. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency
180. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses
181. Elevated blood pressure and enhanced myocardial contractility in mice with severe IGF-1 deficiency
182. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro: Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy
183. Activation of p70 S6 protein kinase is necessary for angiotensin II-induced hypertrophy in neonatal rat cardiac myocytes
184. Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes: Evidence for involvement of p70 S6 kinase
185. Differential activation of p70 and p85 S6 kinase isoforms during cardiac hypertrophy in the adult mammal
186. Phosphoinositide 3-kinase selectively regulates cell size and specific gene expression in the adult mouse heart
187. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart
188. Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes
189. Signaling pathways in cardiac myocyte hypertrophy
190. Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro
191. Basic fibroblast growth factor induces myocardial hypertrophy following acute infarction in rats
192. Continous administration of insulin-like growth factor-1 and basic fibroblast growth factor does not affect left ventricular geometry after acute myocardial infarction in rats
193. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response
194. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes: The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy
195. Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes
196. Adenovirus-mediated overexpression of human transforming growth factor-beta 1 in rat cardiac fibroblasts, myocytes and smooth muscle cells
197. Karliner JS Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts
198. Specificity, diversity, and regulation in TGF-beta superfamily signaling
199. The SRF co-activator, ATF6, is a nuclear target of the TAK 1 pathway in TGFβ signal transduction
200. Association of tyrosmephosphorylated c-Src with the cytoskeleton of hypertrophying myocardium
201. Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes
202. Cardiac-specific overexpression of focal adhesion kinase induces cardiac hypertrophy
203. NRG- 1-induced cardiomyocyte hypenrophy: Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK
204. Neuregulin in cardiac hypertrophy in rats with aortic stenosis: Differential expression of erbB2 and erbB4 receptors
205. Regulation of heparin-binding epidermal growth factor-like growth factor mRNA levels by hypertrophic stimuli in neonatal and adult rat cardiac myocytes
206. The thyroid and the heart
207. Myosin light chain kinase mediates sarcomere organization during cardiac hypertrophy in vitro
208. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes
209. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha
210. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha
211. The protein kinases of Caenorhabditis elegans: A model for signal transduction in multicellular organisms
212. Reversal of left ventricular hypertrophy in hypertensive patients: A meta-analysis of 109 treatment studies
213. Reversal of hypertrophy: An active biologic process